Nonclinical Cardiotoxicity Testing: Stem Cell Use

Prospective identification and potential amelioration of cardiotoxicity is a critical component of contemporary drug development, particularly for targeted therapies (e.g., tyrosine kinases) in oncology that are designed to inhibit critical signaling pathways shared...

Zebrafish: Preclinical Screening and Toxicity Assessment

Zebrafish offer a nonclinical model for the high-throughput screening of drug compounds, including toxicity assessment, with resolution at the cellular level in living vertebrate organisms. لعبة بينغو   These small, freshwater, tropical fish share genetic and...

Adverse Preclinical Events – Now What?

Drug development is a complicated, often convoluted process.  The ability to predict drug toxicity in humans from nonclinical data remains a major challenge. قوانين البوكر   Since you can’t “erase” an adverse event, optimization of preclinical dose...

Is Pharmaceutical Collaboration an Oxymoron?

With the rise of combination therapy – the use drugs with different mechanisms of action to combat a specific disease state – comes the need to address medical costs and reimbursement issues. مواقع رهان   Joint negotiation of package deals with government and...

Dried Blood Spot Analysis: Preclinical Considerations

A previous entry detailed Dried Blood Spot Analysis: Preclinical Pros and Cons.  Additional preclinical considerations include the ambiguity of acceptance by global regulatory agencies, none of which have issued definitive rulings on how they’ll handle New Drug...

Drug Labels: Toxicity or Information Overload?

Side effect overload on drug labels has less to do with true toxicity and drug safety than with manufacturer liability as many people present addiction to drugs and that’s why professional help for drug addiction is important in society.  Examination of more...